Yahoo
NSE - Delayed Quote INR

Cipla Limited (CIPLA.NS)

1,378.90 +20.90 (+1.54%)
At close: October 30 at 3:28:21 PM GMT+5:30
Chart Range Bar
Loading chart for CIPLA.NS
  • Previous Close 1,358.00
  • Open 1,362.00
  • Bid --
  • Ask --
  • Day's Range 1,357.00 - 1,381.70
  • 52 Week Range 1,165.70 - 1,539.70
  • Volume 1,436,439
  • Avg. Volume 958,715
  • Market Cap (intraday) 1.114T
  • Beta (5Y Monthly) 0.09
  • PE Ratio (TTM) 38.47
  • EPS (TTM) 35.84
  • Earnings Date (est.) Jan 21, 2027
  • Forward Dividend & Yield 13.00 (0.94%)
  • Ex-Dividend Date Jun 5, 2026
  • 1y Target Est 1,504.81

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

www.cipla.com

31,369

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

CIPLA.NS
7.90%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

CIPLA.NS
9.63%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

CIPLA.NS
18.87%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

CIPLA.NS
58.79%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY27
Revenue 74.04B
Earnings 8.78B
Profit Margin 11.85%

Q3

FY26

Q4

FY26

Q1

FY27

Q2

FY27

0
20B
40B
60B
9.0%
10.0%
11.0%

Analyst Insights

View More

Analyst Price Targets

1,214.00 Low
1,504.81 Average
1,378.90 Current
1,730.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.35%

  • Return on Assets (ttm)

    5.46%

  • Return on Equity (ttm)

    8.33%

  • Revenue (ttm)

    279.89B

  • Net Income Avi to Common (ttm)

    28.97B

  • Diluted EPS (ttm)

    35.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    82.38B

  • Total Debt/Equity (mrq)

    1.97%

  • Levered Free Cash Flow (ttm)

    -17.86B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: